Stockprowler.com

Stockprowler’s pick this week...

BICO, Inc. (OTCBB: BIKO)
Corporate Web Site: http://www.biocontrol-tech.com/index2.html

Shares Outstanding: 1.64 billion Public Float: 1.63 billion Insider Ownership: 1%
Institutional Ownership: 13
Market Capitalization: $57.6 million
Closing Price Friday 8/24/01: 3.5 cents

BICO, Inc. (OTCBB: BIKO) trading at only 3.5 cents a share recently announced that its subsidiary, Rapid HIV Detection Corp., has received an order for 14,000 of its InstantScreen® Rapid HIV tests from Walter Reed Army Institute of Research for further evaluation by its HIV Research Program in Washington, DC. The additional evaluation of InstantScreen follows results obtained on Walter Reed studies of 592 InstantScreen tests, which demonstrated 100% accuracy. InstantScreen is a finger-prick blood test that can quickly determine if someone is infected with HIV, the virus that can cause AIDS. The advantages of InstantScreen are:

· 100% accurate -- In combined evaluations on nearly 1200 specimens by institutions such as Walter Reed Army Institute; Noguchi Memorial Institute for Medical Research in Accra, Ghana; World Health Organization; and the National Institute for Virology in South Africa, InstantScreen has shown 100% accuracy in detecting both those infected with the HIV virus and those not infected when compared to the world wide accepted laboratory tests known as ELISA (for initial screening) and Western Blot (for confirmation).

· Instant results -- Within 30 seconds or less the results are known Simple to use -- InstantScreen requires no special training, extra equipment, or refrigeration, uses only a small amount of finger prick blood, and anyone who can read at least on an elementary level can administer the test

· Affordable -- $10 or less in most instances

The data from Walter Reed's recent evaluation of rapid HIV tests was presented on Monday, August 13, 2001 at the National HIV Prevention Conference in Atlanta, Georgia. During the conference, Dr. Nelson T. Michael, Chief - Department of Molecular Diagnostics and Pathogenesis at Walter Reed and Dr. Bernard Branson, Medical Epidemiologist for the CDC's National Center for HIV, STD and TB Prevention, stressed the need for rapid HIV testing as the first step to combat the HIV/AIDS pandemic not only in the United States but worldwide as well.

More than 40% of HIV positive Americans don’t know they are infected until they develop full-blown AIDS, sometimes missing out on treatment that could prolong their lives considerably if administered soon after the initial HIV infection. Dr. Ronald Valdiserri, deputy director of HIV prevention for the U.S. Centers for Disease Control in Atlanta, stated, “ Significant numbers of people with HIV are only finding out about their infection when they feel sick. We must reach these individuals at an earlier stage of infection for their own health and to prevent transmission to others.” The latest data shows that the decline in new reported AIDS cases is flattening out, causing health officials to express concern that “the country may be headed for a new wave of HIV/AIDS infections.”

The InstantScreen test performs very accurately due to its novel genetically engineered “designer” antigens, which recognize only the HIV virus, eliminating unspecific reactions that often give false positive results, especially where there is high incidence of malaria, tuberculosis, and hepatitis. The test is easy to use, requiring no special training, additional equipment, or refrigeration, which makes it perfectly suited for mass testing in developing countries and equally suitable for clinics, doctor's offices, and even home use where permitted.

In addition, newly formed BICO subsidiary, Rapid HIV Detection Corp., will market two recently acquired companion rapid HIV diagnostic tests, which were developed at, and are manufactured by, the German-American Institute for Applied Biomedical Research, GmbH (GAIFAR) in Potsdam, Germany: InstantConfirm(TM), an 8-minute Western-Blot Type HIV confirmation test; and InstantDifferentiate(TM), used to determine if the patient is infected with either HIV-1 or HIV-2. InstantConfirm is the first such test to successfully transform the widely used gold standard Western Blot laboratory test into a rapid format, usable immediately to confirm a positive result. Altogether, the three tests can be used to diagnose in approximately ten minutes or less a person's HIV infection status, confirm that diagnosis and then determine if a confirmed infection is the less aggressive HIV-2 or the more aggressive HIV-1.

InstantScreen was tested against the widely internationally accepted laboratory tests known as ELISA (screening test) and Western Blot (confirmation test) with 100% accuracy. InstantConfirm is the first test to transform the widely used gold standard Western Blot laboratory test into a rapid format, usable immediately to confirm a positive result. Confirmation results are obtained in 8 minutes or less. No other test on the market has a companion rapid confirmation test. Use of the Western Blot laboratory confirmation test usually costs $50-$90 each. Necessary manpower and transportation to and from the laboratory from the point of screening would be an extra cost. Results would take days or weeks. InstantConfirm results cost a fraction and the results are known before the patient leaves the testing site.

BICO, Inc. acquired the exclusive worldwide marketing rights from GAIFAR in Potsdam, Germany, where InstantScreen was developed by Dr. Heinrich Repke. Dr. Repke has a Ph.D in Immunology, a D.Sc in Molecular Pharmacology, and spent 5 years as an Assistant Professor of Pathology and of Genetics at Harvard Medical School.

BICO is currently in discussions with various political officials, corporations, and other groups regarding use of the diagnostic test(s) wherever AIDS is rampant. Initial target markets for the diagnostics are Africa, India, South America, and the Caribbean, where AIDS is prevalent and the Germany-produced products do not need FDA approval. However, GAIFAR will immediately begin the US FDA approval process, which is expected to be fast- tracked due to the significant need for such a rapid accurate HIV test.

BICO, Inc. primary business is the development and manufacture of new devices, which include models of a non-invasive glucose sensor, procedures relating to the use of regional extracorporeal hyperthermia in the treatment of cancer and environmental products that help to clean up oil spills. The company's non-invasive glucose sensor helps diabetics measure their glucose without pricking their fingers or having to draw blood. Regional extracorporeal hyperthermia is a system that recirculates the patient's blood in a specific area of the body after the blood has been heated outside the body. The recirculated blood's higher temperature helps treat certain diseases by inducing an artificial fever that kills targeted cells. The company was incorporated in 1972. In June 2000, the company changed its corporate name from Biocontrol Technology, Inc. to BICO, Incorporated.

The company has several subsidiaries in addition to the recently formed Rapid HIV Detection Corp. each specializing in different projects. Diasensor.com, Inc. manages the non-invasive glucose sensor project. ViaCirQ, Inc., formerly IDT, handles the hyperthermia project, a technology called the ThermoChem System, which induces an artificial fever to help treat diseases. Petrol Rem, Inc. handles BICO's environmental products PRP, BIOSOK and BIOBOOM, which help clean up oil spills and other pollutants in water.

It is the opinion of Stockprowler.com that shares of BIKO are poised to explode when/if the medical community in the U.S. officially recognizes InstantScreen as the HIV “test of choice”. Recognition by the Walter Reed Army Institute of Research and a very favorable reception to the InstantScreen test at the recent HIV Prevention Conference in Atlanta are giant steps toward that goal. Despite the very large float here (over 1 billion shares) a dramatic move in the stock price of BIKO is possible, especially in light of the recent heavy trading volumes in the stock... a 10 bagger here is not out of the realm of possibility. Shares of BIKO closed up 50% on Friday at 3.5 cents on 153,750,700 shares traded. Stockprowler readers are encouraged to visit the BIKO company web site for further information.

Stockprowler.com did not receive compensation of any kind from the company or third parties for writing this report. Readers are urged to read the company SEC filings and do their own due diligence before investing in this or any other stock.

Good Trading... Stockprowler